Dosage & Administration

Cutaquig is for subcutaneous use only

Do not inject into a blood vessel.

  • Before switching to cutaquig, obtain patient’s serum immunoglobulin G (IgG) trough level to guide subsequent dose adjustments. Individualize dose based on patient’s pharmacokinetic and clinical response. Monitor serum IgG trough levels regularly to guide subsequent dose adjustments as needed.
Ensure that patients have received treatment at regular intervals for at least 3 months
To convert the dose (in grams) to milliliters (mL), multiply the calculated dose (in grams) by 6
Provided total weekly dose is maintained, any dosing interval from daily up to weekly can be used and will result in systemic IgG exposure that is comparable to the previous IVIg treatment
Recommended Infusion Volume, Frequency and Rate
Recommended Infusion VolumeFor SCIg-naïve patients, 25 mL per infusion site (maximum). If tolerated, volume can be gradually increased up to 40 mL per site.
Infusion FrequencyWeekly
Infusion Rate
(Per Hour)
Per site
First 6 infusions:
15-20 mL/hour/site
Subsequently:
25 mL/hour/site
For all Sites combined 
First 6 infusions:
30 mL/hour
If tolerated, gradually increase to 50 mL, then 80 mL, up to 100 mL/hour

Please see full prescribing information for complete information on cutaquig dosing.
Dose adjustment: Over time the cutaquig dose may need to be individualized for each patient, dependent on pharmacokinetic and clinical response and on the desired IgG trough level. Measure patient’s serum IgG trough level 2 to 3 months after switching to cutaquig or after the last cutaquig dose adjustment, in order to determine if a dose adjustment is necessary.

  • Calculate the difference (in mg/dL) between the patient’s target serum IgG trough level and the IgG trough level obtained during subcutaneous treatment with cutaquig. Find this difference in column 1 of the table below and locate the corresponding adjustment amount of cutaquig in mL/administration according to the body weight of the patient.

Incremental adjustment (mL) of weekly cutaquig dosing based on the calculated difference between actual IgG trough level and the target trough level for the patient.*

Difference from Target Serum IgG Trough LevelWeight-adjusted Dose Increment (mL*)
Body Weight
30 kg50 kg70 kg90 kg110 kg
50 mg/dl346810
100 mg/dl59121619
200 mg/dl1118253239
300 mg/dl1626374758

*Derived from a linear regression model of trough levels and weekly dose per kg body weight.

  • Use patient’s clinical response as primary point to consider for any dose adjustment. Additional dose increments may be indicated based on the patient’s clinical response (i.e., infection frequency and severity).

Medical chart icon

Example: A patient with body weight of 70 kg is treated weekly and has trough level of 600 mg/dL, but target trough level is 900 mg/dL – a difference of 300 mg/dL.
The recommended increase in weekly dose would be 37 mL.

Monitor patient’s clinical response and periodically check trough IgG levels, and repeat dose adjustment as needed.

Administration

  • Cutaquig should be administered by a healthcare professional, or by caregiver or self-administered by the patient after appropriate training
  • Cutaquig may be infused in the following areas: abdomen, thigh, upper arm, and/or upper leg/hip area
  • Cutaquig may be infused simultaneously into up to 6 different sites. Infusion sites should be at least 2 inches (5 cm) apart. Rotate infusion sites between subsequent administrations.

Diagram showing where to insert cutaquig

Patient inserting cutaquig into stomach

Preparation and handling

Check the product expiration date on the vial label. Do not use beyond the expiration date.
Do not freeze. Do not use frozen product.
Do not mix cutaquig with other products
Do not shake the cutaquig vial
Use aseptic technique when preparing and administering cutaquig
Prior to administration, visually inspect each vial of cutaquig for particulate matter, whenever the solution and container permit

The cutaquig vial is for single-use only. Discard any unused product after each infusion in accordance with local requirements.

Review information and recommendations about cutaquig supply and storage.

Learn More

References:
  1. Cutaquig® (Immune Globulin Subcutaneous (Human) – hipp), 16.5% solution. Full Prescribing Information. Octapharma USA, December 2019.